20
Participants
Start Date
September 30, 2011
Primary Completion Date
November 30, 2014
Study Completion Date
October 31, 2015
Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
Peter Munk Cardiac Center/ University Health Network, Toronto
Collaborators (1)
Miltenyi Biotec, Inc.
INDUSTRY
University Health Network, Toronto
OTHER